The Genetics of Alzheimer’s Disease: Introduction and Perspective for the Future



Our understanding of the genetics of Alzheimer’s disease (AD) has progressed considerably in the last few years, thanks to the contribution of genome-wide association studies (GWAS). We now have ten common variants that associate with risk with the promise of more to come. Other than APOE4 each has a small risk, but collectively their contribution adds to our genetic understanding and makes an impact on possible novel mechanisms of disease. Advances in technology, particularly next generation sequencing approaches, are also starting to explain the genetic architecture of the disease at an increasingly fine level. Once we have a complete understanding of AD risk factors, diagnostic testing becomes a reality. Whilst currently there is little to offer such individuals, their identification could well be worthwhile as they are the patients most likely to benefit from early intervention with emerging therapies.


Next Generation Sequencing Rare Variant Next Generation Sequencing Approach Genetic Understanding Index SNPs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Harold D et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41:1088–1093PubMedCrossRefGoogle Scholar
  2. 2.
    Lambert J-C et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41:1094–1099PubMedCrossRefGoogle Scholar
  3. 3.
    Seshadri S et al (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303:1832–1840PubMedCrossRefGoogle Scholar
  4. 4.
    Hollingworth P et al (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43:429–435PubMedCrossRefGoogle Scholar
  5. 5.
    Naj AC et al (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43:436–441PubMedCrossRefGoogle Scholar
  6. 6.
    Jonsson T et al (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368(2):107–116PubMedCrossRefGoogle Scholar
  7. 7.
    Guerreiro R et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368(2):117–127PubMedCrossRefGoogle Scholar
  8. 8.
    Strittmatter WJ et al (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90:1977–1981PubMedCrossRefGoogle Scholar
  9. 9.
    Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer’s disease: back to the future. Neuron 68:270–281PubMedCrossRefGoogle Scholar
  10. 10.
    Hollingworth P et al (2011) Alzheimer’s disease genetics: current knowledge and future challenges. Int J Geriatr Psychiatry 26:793–802PubMedCrossRefGoogle Scholar
  11. 11.
    Bras J, Guerreiro R, Hardy J (2012) Use of next-generation sequencing and other whole genome strategies to dissect neurological disease. Nat Rev Neurosci 13:453–464PubMedCrossRefGoogle Scholar
  12. 12.
    Bertram L et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39:17–23 [Updated 18 April 2011, Accessed 23 December 2012]PubMedCrossRefGoogle Scholar
  13. 13.
    Bettens K, Sleegers K, Van Broeckhoven C (2010) Current satus on Alzheimer disease molecular genetics; from past, to present, to future. Hum Mol Genet 19:R4–R11PubMedCrossRefGoogle Scholar
  14. 14.
    Hardy J, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185PubMedCrossRefGoogle Scholar
  15. 15.
    Guerreiro R, Gustafson DR, Hardy J (2012) The genetic archetecture of Alzheimer’s disease; beyond APP, PSENs and APOE. Neurobiol Aging 33:437–456PubMedCrossRefGoogle Scholar
  16. 16.
    Jones L et al (2010) Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzhemer’s disease. PLoS One 5:e13950PubMedCrossRefGoogle Scholar
  17. 17.
    Schellenberg GD, Montine TJ (2012) The genetics and neuropathology of Alzheimer’s disease. Acta Neuropathol 124:305–323PubMedCrossRefGoogle Scholar
  18. 18.
    Jonsson T et al (2012) A mutation in APP protects against Alzheimer’s disease and age-relayed cognitive decline. Nature 488:96–99PubMedCrossRefGoogle Scholar
  19. 19.
    Gao J et al (2011) Am exploratory study on CLU, CR1 and PICALM and Parkinson disease. PLoS One 6:e24211PubMedCrossRefGoogle Scholar
  20. 20.
    Chang D, Keinan A (2012) Predicting signatures of ‘Synthetic Associations’ and ‘Natural Associations’ from empirical patterns of human genetic variation. PLoS Comput Biol 8:e1002600PubMedCrossRefGoogle Scholar
  21. 21.
    Cruchaga C et al (2012) Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS One 7:e31039PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Human Genetics, School of Molecular Medical Sciences, Queen’s Medical CentreUniversity of NottinghamNottinghamUK
  2. 2.Department of NeuroscienceMayo Clinic College of MedicineJacksonvilleUSA

Personalised recommendations